- Home
- FICO vs MIST Comparison
FICO vs MIST Comparison
Compare FICO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FICO
- MIST
- Stock Information
- Founded
- FICO 1956
- MIST 2003
- Country
- FICO United States
- MIST Canada
- Employees
- FICO N/A
- MIST N/A
- Industry
- FICO Business Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- FICO Consumer Discretionary
- MIST Health Care
- Exchange
- FICO Nasdaq
- MIST Nasdaq
- Market Cap
- FICO 48.4B
- MIST 53.9M
- IPO Year
- FICO 1987
- MIST N/A
- Fundamental
- Price
- FICO $2,115.00
- MIST $1.16
- Analyst Decision
- FICO Buy
- MIST Strong Buy
- Analyst Count
- FICO 12
- MIST 2
- Target Price
- FICO $2,236.75
- MIST $9.50
- AVG Volume (30 Days)
- FICO 182.1K
- MIST 1.6M
- Earning Date
- FICO 04-29-2025
- MIST 05-20-2025
- Dividend Yield
- FICO N/A
- MIST N/A
- EPS Growth
- FICO 21.78
- MIST N/A
- EPS
- FICO 23.21
- MIST N/A
- Revenue
- FICO $1,840,361,000.00
- MIST N/A
- Revenue This Year
- FICO $17.79
- MIST N/A
- Revenue Next Year
- FICO $15.57
- MIST N/A
- P/E Ratio
- FICO $90.72
- MIST N/A
- Revenue Growth
- FICO 14.71
- MIST N/A
- 52 Week Low
- FICO $1,240.31
- MIST $0.63
- 52 Week High
- FICO $2,402.52
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- FICO 68.95
- MIST 46.48
- Support Level
- FICO $2,035.94
- MIST $1.28
- Resistance Level
- FICO $2,112.05
- MIST $1.32
- Average True Range (ATR)
- FICO 53.87
- MIST 0.12
- MACD
- FICO 15.94
- MIST 0.03
- Stochastic Oscillator
- FICO 94.48
- MIST 38.80
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).